KalVista Pharmaceuticals
KALV
KALV was delisted on the 10th of June, 2026.
73 hedge funds and large institutions have $244M invested in KalVista Pharmaceuticals in 2019 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 28 increasing their positions, 14 reducing their positions, and 17 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 14
67% more funds holding in top 10
Funds holding in top 10: 3 → 5 (+2)
60% more capital invested
Capital invested by funds: $153M → $244M (+$91.4M)
12% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 17
2.98% more ownership
Funds ownership: 73.98% → 76.96% (+3%)
4% less funds holding
Funds holding: 76 → 73 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$9.68M |
| 2 |
Franklin Resources
San Mateo,
California
|
+$3.7M |
| 3 |
Victory Capital Management
San Antonio,
Texas
|
+$3.57M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$2.49M |
| 5 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$1.93M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$10.3M |
| 2 |
PC
Polar Capital
London,
United Kingdom
|
-$9.72M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
-$2.61M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$1.01M |
| 5 |
Neuberger Berman Group
New York
|
-$682K |
KALV Hedge Fund Activity: Q4 2019 in Review
73 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in KalVista Pharmaceuticals (KALV) for Q4 2019, worth a combined $244M — up 60% from $153M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new KALV positions and 17 closed out — a net gain of 2 holders — while 28 added to existing stakes and 14 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $9.68M. The largest seller was Deerfield Management, exiting entirely with an estimated $10.3M sold.
- 73 institutional investors held KalVista Pharmaceuticals (KALV) as of Q4 2019, down from 76 in Q3 2019.
- Funds reported $244M of KalVista Pharmaceuticals stock for Q4 2019, up 60% quarter-over-quarter.
- 19 funds opened new KalVista Pharmaceuticals positions in Q4 2019 and 17 closed out, a net change of +2 holders.
- The largest KalVista Pharmaceuticals buyer in Q4 2019 was Fidelity Investments, an estimated $9.68M added.
- The largest KalVista Pharmaceuticals seller in Q4 2019 was Deerfield Management, an estimated $10.3M sold.
Based on aggregated 13F filings for Q4 2019.